DK2300459T3 - Nye fenylpyrazinoner som kinasehæmmere - Google Patents

Nye fenylpyrazinoner som kinasehæmmere

Info

Publication number: DK2300459T3
Authority: DK; Denmark
Prior art keywords: pyrazinones; kinase inhibitors; new phenyl; phenyl; new
Prior art date: 2008-07-02

Application number

DK09772333.2T

Other languages

English (en)

Inventor

Nolan James Dewdney

Yan Lou

Eric Brian Sjogren

Michael Soth

Zachary Kevin Sweeney

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-02

Filing date

2009-06-22

Publication date

2013-09-02

2009-06-22 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2013-09-02 Application granted granted Critical

2013-09-02 Publication of DK2300459T3 publication Critical patent/DK2300459T3/da

Links

CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK09772333.2T 2008-07-02 2009-06-22 Nye fenylpyrazinoner som kinasehæmmere DK2300459T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7751008P	2008-07-02	2008-07-02
PCT/EP2009/057707 WO2010000633A1 (en)	2008-07-02	2009-06-22	Novel phenylpyrazinones as kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK2300459T3 true DK2300459T3 (da)	2013-09-02

Family

ID=40940244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09772333.2T DK2300459T3 (da)	2008-07-02	2009-06-22	Nye fenylpyrazinoner som kinasehæmmere

Country Status (24)

Country	Link
US (1)	US8536166B2 (da)
EP (1)	EP2300459B1 (da)
JP (1)	JP5490789B2 (da)
KR (2)	KR101320763B1 (da)
CN (1)	CN102083819B (da)
AR (1)	AR072545A1 (da)
AU (1)	AU2009265813B2 (da)
BR (1)	BRPI0913879A2 (da)
CA (1)	CA2728683C (da)
CL (1)	CL2010001608A1 (da)
CY (1)	CY1114223T1 (da)
DK (1)	DK2300459T3 (da)
ES (1)	ES2420854T3 (da)
HR (1)	HRP20130698T1 (da)
IL (1)	IL209729A0 (da)
MX (1)	MX2010013478A (da)
PE (1)	PE20110164A1 (da)
PL (1)	PL2300459T3 (da)
PT (1)	PT2300459E (da)
RU (1)	RU2507202C2 (da)
SI (1)	SI2300459T1 (da)
TW (1)	TWI401083B (da)
WO (1)	WO2010000633A1 (da)
ZA (1)	ZA201008808B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) *	2009-04-24	2010-10-28	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
KR101862327B1 (ko)	2010-05-07	2018-05-29	질레드 코네티컷 인코포레이티드	피리돈 및 아자-피리돈 화합물 및 사용 방법
AR082590A1 (es)	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
CA2809836C (en) *	2010-09-01	2019-01-15	Gilead Connecticut, Inc.	Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
KR20140058543A (ko)	2011-07-08	2014-05-14	노파르티스 아게	신규 피롤로 피리미딘 유도체
UA111756C2 (uk)	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
RU2628616C2 (ru)	2011-11-03	2017-08-21	Ф. Хоффманн-Ля Рош Аг	Бициклические соединения пиперазина
MX2014005289A (es)	2011-11-03	2014-05-30	Hoffmann La Roche	Compuestos de piperazina alquilados.
WO2013067264A1 (en)	2011-11-03	2013-05-10	Genentech, Inc.	8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
US9365566B2 (en)	2012-03-27	2016-06-14	Takeda Pharmaceutical Company Limited	Cinnoline derivatives
AU2013250726B2 (en)	2012-04-20	2017-01-05	Advinus Therapeutics Limited	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
KR20150054994A (ko) *	2012-09-13	2015-05-20	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
WO2014108820A1 (en) *	2013-01-08	2014-07-17	Aurigene Discovery Technologies Limited	Substituted 2-pyrazinone derivatives as kinase inhibitors
WO2014125410A1 (en) *	2013-02-12	2014-08-21	Aurigene Discovery Technologies Limited	N-substituted heterocyclic derivatives as kinase inhibitors
EP2964627B1 (en)	2013-03-05	2017-03-01	F. Hoffmann-La Roche AG	Inhibitors of bruton's tyrosine kinase
JO3377B1 (ar)	2013-03-11	2019-03-13	Takeda Pharmaceuticals Co	مشتقات بيريدينيل وبيريدينيل مندمج
HRP20170217T1 (hr)	2013-04-25	2017-04-21	Beigene, Ltd.	Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
CN104177338B (zh) *	2013-05-22	2018-04-03	南京勇山生物科技有限公司	一类布鲁顿激酶抑制剂
CN104211703B (zh) *	2013-05-30	2018-04-03	南京勇山生物科技有限公司	一类作为布鲁顿激酶抑制剂的稠杂环化合物
RU2016101548A (ru) *	2013-07-03	2017-08-08	Ф. Хоффманн-Ля Рош Аг	Соединения амидов гетероарилпиридона и азапиридона
KR101742550B1 (ko)	2013-07-26	2017-06-01	카나 바이오사이언스, 인코포레이션	신규 트리아진 유도체
CA2919522C (en)	2013-07-30	2019-02-26	Gilead Connecticut, Inc.	Formulation of syk inhibitors
EA029281B1 (ru)	2013-07-30	2018-03-30	Джилид Коннектикут, Инк.	Полиморф ингибиторов syk
EA034666B1 (ru)	2013-09-13	2020-03-04	Бейджин Свитзерланд Гмбх	Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
WO2015082583A1 (en)	2013-12-05	2015-06-11	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
TWI662037B (zh)	2013-12-23	2019-06-11	美商基利科學股份有限公司	脾酪胺酸激酶抑制劑
TWI726608B (zh)	2014-07-03	2021-05-01	英屬開曼群島商百濟神州有限公司	抗pd-l1抗體及其作為治療及診斷之用途
EP3042903B1 (en) *	2015-01-06	2019-08-14	Impetis Biosciences Ltd.	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US20180140602A1 (en)	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA3019134C (en)	2016-03-31	2024-04-23	Takeda Pharmaceutical Company Limited	Isoquinolinyl triazolone complexes
US10864203B2 (en)	2016-07-05	2020-12-15	Beigene, Ltd.	Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CA3033827A1 (en)	2016-08-16	2018-02-22	Beigene, Ltd.	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt)	2016-08-19	2024-02-21	Beigene Switzerland Gmbh	Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CN109982687A (zh)	2016-09-19	2019-07-05	梅制药公司	联合疗法
US10842878B2 (en)	2016-11-22	2020-11-24	Dana-Farber Cancer Institute, Inc.	Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
EP3573989A4 (en)	2017-01-25	2020-11-18	Beigene, Ltd.	CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
TW202515616A (zh)	2017-06-26	2025-04-16	英屬開曼群島商百濟神州有限公司	抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019034009A1 (en)	2017-08-12	2019-02-21	Beigene, Ltd.	BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
CA3073871A1 (en)	2017-08-25	2019-02-28	Gilead Sciences, Inc.	Polymorphs of syk inhibitors
CN111801334B (zh)	2017-11-29	2023-06-09	百济神州瑞士有限责任公司	使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN113950479A (zh)	2019-02-22	2022-01-18	克洛诺斯生物股份有限公司	作为syk抑制剂的缩合吡嗪的固体形式
WO2020249001A1 (zh)	2019-06-10	2020-12-17	百济神州瑞士有限责任公司	一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
US11786531B1 (en)	2022-06-08	2023-10-17	Beigene Switzerland Gmbh	Methods of treating B-cell proliferative disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002506856A (ja) *	1998-03-14	2002-03-05	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
CA2419224A1 (en) *	2000-09-15	2002-03-21	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
WO2005035527A1 (en) *	2003-10-14	2005-04-21	Pharmacia Corporation	Substituted pyrazinone compounds for the treatment of inflammation
CA2601628C (en) *	2005-03-10	2014-05-13	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
WO2006124731A2 (en)	2005-05-12	2006-11-23	Irm Llc	Compounds and compositions as protein kinase inhibitors
ATE482958T1 (de)	2005-08-09	2010-10-15	Irm Llc	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
EP1919905B1 (en)	2005-08-29	2011-02-23	Vertex Pharmaceuticals Incorporated	3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases
WO2007027594A1 (en)	2005-08-29	2007-03-08	Vertex Pharmaceuticals Incorporated	3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
JP2009506123A (ja)	2005-08-29	2009-02-12	バーテックスファーマシューティカルズインコーポレイテッド	非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
MX2008003337A (es) *	2005-09-09	2008-09-26	Vertex Pharma	Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
JP2009530342A (ja) *	2006-03-20	2009-08-27	エフ．ホフマン−ラロシュアーゲー	Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
US20090312321A1 (en)	2006-05-15	2009-12-17	Irm Llc	Compositions and methods for fgf receptor kinases inhibitors
AR063707A1 (es)	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
AR063706A1 (es) *	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US7838523B2 (en) *	2006-09-11	2010-11-23	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
WO2008033858A2 (en) *	2006-09-11	2008-03-20	Cgi Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
CL2008002793A1 (es)	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009053269A1 (en)	2007-10-23	2009-04-30	F. Hoffmann-La Roche Ag	Novel kinase inhibitors
ES2552320T3 (es) *	2008-06-24	2015-11-27	F. Hoffmann-La Roche Ag	Nuevas piridín-2-onas y piridazín-3-onas sustituidas
AU2010204106B2 (en) *	2009-01-08	2014-05-08	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase

2009
- 2009-06-22 BR BRPI0913879A patent/BRPI0913879A2/pt not_active IP Right Cessation
- 2009-06-22 RU RU2011103234/04A patent/RU2507202C2/ru not_active IP Right Cessation
- 2009-06-22 SI SI200930631T patent/SI2300459T1/sl unknown
- 2009-06-22 EP EP09772333.2A patent/EP2300459B1/en not_active Not-in-force
- 2009-06-22 KR KR1020107029738A patent/KR101320763B1/ko not_active Expired - Fee Related
- 2009-06-22 JP JP2011515329A patent/JP5490789B2/ja not_active Expired - Fee Related
- 2009-06-22 CA CA2728683A patent/CA2728683C/en not_active Expired - Fee Related
- 2009-06-22 DK DK09772333.2T patent/DK2300459T3/da active
- 2009-06-22 PT PT97723332T patent/PT2300459E/pt unknown
- 2009-06-22 PE PE2010001208A patent/PE20110164A1/es not_active Application Discontinuation
- 2009-06-22 CN CN200980125623.9A patent/CN102083819B/zh not_active Expired - Fee Related
- 2009-06-22 MX MX2010013478A patent/MX2010013478A/es active IP Right Grant
- 2009-06-22 WO PCT/EP2009/057707 patent/WO2010000633A1/en not_active Ceased
- 2009-06-22 PL PL09772333T patent/PL2300459T3/pl unknown
- 2009-06-22 KR KR1020137016860A patent/KR101523451B1/ko not_active Expired - Fee Related
- 2009-06-22 ES ES09772333T patent/ES2420854T3/es active Active
- 2009-06-22 HR HRP20130698AT patent/HRP20130698T1/hr unknown
- 2009-06-22 AU AU2009265813A patent/AU2009265813B2/en not_active Expired - Fee Related
- 2009-06-30 TW TW098122087A patent/TWI401083B/zh not_active IP Right Cessation
- 2009-07-01 AR ARP090102453A patent/AR072545A1/es not_active Application Discontinuation
- 2009-07-01 US US12/459,595 patent/US8536166B2/en not_active Expired - Fee Related
2010
- 2010-12-02 IL IL209729A patent/IL209729A0/en unknown
- 2010-12-07 ZA ZA2010/08808A patent/ZA201008808B/en unknown
- 2010-12-29 CL CL2010001608A patent/CL2010001608A1/es unknown
2013
- 2013-08-01 CY CY20131100661T patent/CY1114223T1/el unknown

Also Published As

Publication number	Publication date
CY1114223T1 (el)	2016-08-31
AU2009265813B2 (en)	2014-04-10
KR101320763B1 (ko)	2013-10-21
TWI401083B (zh)	2013-07-11
RU2507202C2 (ru)	2014-02-20
RU2011103234A (ru)	2012-08-10
IL209729A0 (en)	2011-02-28
BRPI0913879A2 (pt)	2019-09-24
US20100004231A1 (en)	2010-01-07
TW201004938A (en)	2010-02-01
SI2300459T1 (sl)	2013-07-31
PL2300459T3 (pl)	2013-10-31
KR101523451B1 (ko)	2015-05-27
CA2728683A1 (en)	2010-01-07
KR20130093156A (ko)	2013-08-21
KR20110020872A (ko)	2011-03-03
PT2300459E (pt)	2013-07-04
MX2010013478A (es)	2010-12-20
JP5490789B2 (ja)	2014-05-14
JP2011526279A (ja)	2011-10-06
US8536166B2 (en)	2013-09-17
PE20110164A1 (es)	2011-03-28
AR072545A1 (es)	2010-09-08
HRP20130698T1 (en)	2013-10-11
CN102083819A (zh)	2011-06-01
ES2420854T3 (es)	2013-08-27
EP2300459A1 (en)	2011-03-30
ZA201008808B (en)	2011-10-26
EP2300459B1 (en)	2013-05-29
AU2009265813A1 (en)	2010-01-07
WO2010000633A1 (en)	2010-01-07
CL2010001608A1 (es)	2011-05-13
CA2728683C (en)	2017-05-02
CN102083819B (zh)	2014-07-09

Publication	Publication Date	Title
DK2300459T3 (da)	2013-09-02	Nye fenylpyrazinoner som kinasehæmmere
CY2020024I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
IL280173A (en)	2021-03-01	Inhibitors of brutons tyrosine kinase
CY2019009I2 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
LTPA2017039I1 (lt)	2017-12-11	Pirolopirimidino junginiai, kaip CDK inhibitoriai
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
DK2300013T4 (da)	2025-02-03	Phosphorderivater som kinasehæmmere
DK2021335T3 (da)	2011-09-05	Heterocykliske forbindelser som C-FMS-kinasehæmmere
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
LT3354650T (lt)	2022-06-27	Junginiai, naudingi kaip atr kinazės inhibitoriai
DK2220070T3 (da)	2011-07-04	2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2315756T3 (da)	2014-10-13	1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2318389T3 (da)	2013-09-30	Pyridazinderivater som SMO-inhibitorer
ATE541850T1 (de)	2012-02-15	Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
DK3354652T3 (da)	2020-05-18	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
DK2414362T3 (da)	2014-09-22	Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
BRPI0817843A2 (pt)	2015-04-07	Inibidores da quinase c-fms
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2086960T3 (da)	2014-06-10	Nye inhibitorer af glutaminylcyclase.
DK2283024T3 (da)	2013-08-05	4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
PL3178818T3 (pl)	2019-11-29	Inhibitory kinazy pirazolilochinoksalinowej
BRPI0811212A2 (pt)	2014-10-29	Inibidores de p70 quinase
EP2632898A4 (en)	2014-04-02	HETEROCYCLIC TYROSINE KINASE HEMMER
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer